Abstract
BACKGROUND: Type 2 diabetes mellitus (T2DM) is a progressive metabolic disorder characterized by insulin resistance and hyperglycemia. Although metformin remains a first-line therapy, interest in plant-based adjuncts like _Gymnema sylvestre _is increasing due to their potential antidiabetic properties. OBJECTIVES: The study aimed to assess the efficacy of the combination of G. sylvestre and metformin in reducing blood glucose levels and body weight in streptozotocin-induced diabetic rats. Additionally, it sought to compare the effectiveness of this combination therapy with metformin alone in achieving glycemic control and weight reduction. The investigation also explored the potential benefits of the combination treatment on lipid profile and renal function, providing a broader understanding of its therapeutic impact in managing type 2 diabetes mellitus. METHOD: Thirty male Sprague Dawley rats (150 ± 20 g) were divided into five groups: normal control, diabetic control, metformin-treated, GS-treated, and combination-treated. T2DM was induced by administering a high-fat diet for 21 days followed by two low-dose intraperitoneal injections of streptozotocin (25 mg/kg, five days apart). Rats with fasting blood glucose (FBG) ≥270 mg/dL were selected for treatment, which continued for 28 days. RESULTS: All treatment groups showed significant improvements in biochemical parameters compared to diabetic controls (p < 0.05). Metformin and combination therapy groups demonstrated greater reductions in FBG, cholesterol, creatinine, and HbA1c levels. While GS alone had modest antidiabetic effects, its combination with metformin enhanced efficacy, especially in glycemic control and lipid profile. Metformin alone showed superior effects on renal function. CONCLUSION: G. sylvestre exhibits antidiabetic activity, which is amplified in combination with metformin. Although metformin alone remains more effective, the combination therapy offers additional benefits in T2DM management.
Full text
621 characters
· extracted from
oa-doi-fallback
· click to expand
There is a newer version available for this {{ publicationType }}. View latest version
{{ publication.field_name }}
{{ publication.subfield_name }}
Copyright: © {{ publicationYear }} {{ publication.presentation_authors[0].full_name + (publication.presentation_authors.length > 1 ? ' et al' : '') }}. This is an open access publication distributed under the terms of the CC BY 4.0 License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Check the {{ publicationType | capitalize }} Source for copyright and license information.
Listen on
Text is read by the "Ask this paper" AI Q&A widget below.
Extraction quality varies by source — PMC NXML preserves structure
cleanly, OA-HTML may include some navigation residue, and OA-PDF can
have broken hyphenation. The publisher copy
(via DOI)
is the canonical version.